A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJ302-IM in Healthy Volunteers

Key Inclusion Criteria:

• Male or female, non-smokers (no use of tobacco or nicotine products within 3 monthsprior to screening), ≥ 18 and ≤ 55years of age, with body mass index (BMI) ≥ 18.5and ≤ 30.0 kg/m2 and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females.

• Normal renal function at screening.

• Healthy as defined by:

• The absence of clinically significant illness and surgery within 4 weeks priorto study drug administration.

• The absence of clinically significant history of neurological, endocrine,cardiovascular, respiratory, hematological, immunological, psychiatric,depression, attempted suicide, gastrointestinal, renal, hepatic, and metabolicdisease.

• Able to understand the study procedures and provide signed informed consent toparticipate in the study

Key Exclusion Criteria:

• Any clinically significant abnormal finding at physical examination

• Any lifetime suicidal behavior or suicidal ideation of type 4 (active suicidalideation with some intent to act, without specific plan) or type 5 (active suicidalideation with specific plan and intent) in the 2 years before screening based on theC-SSRS

• Clinically significant abnormal laboratory test results or positive serology testresults for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody,or human immunodeficiency virus (HIV) antigen and antibody, at screening

• Positive pregnancy test or lactating female volunteers

• Positive urine drug screen, urine cotinine test, or alcohol breath test at screeningand on Day -1

• History of significant allergic reactions to any drug

• Known allergy or hypersensitivity to histone deacetylase 6 (HDAC6) inhibitors or itsderivatives and/or any study product excipients

• Clinically significant ECG abnormalities or vital signs abnormalities at screening

• History of drug abuse or recreational use of soft drugs or hard drugs

• History of alcohol abuse

• History of smoking or uses other nicotine-containing products

• Undergone major surgery ≤ 2 months before study drug administration

• History of clinically significant opportunistic infection or serious local infectionor significant medical/surgical procedure or trauma, or any current infection.

• Use of medications for the timeframes specified in the protocol

• Received any investigational drug or any investigational device or any biologicalproduct within the timeframes specified in the protocol

• Tattoos, sunburn, scarring or anything that may interfere with evaluation of theinjection site